vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.
Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $270.7M, roughly 1.8× BALCHEM CORP). BALCHEM CORP runs the higher net margin — 14.9% vs 6.8%, a 8.1% gap on every dollar of revenue. On growth, BALCHEM CORP posted the faster year-over-year revenue change (8.1% vs -1.7%). Over the past eight quarters, BALCHEM CORP's revenue compounded faster (7.5% CAGR vs -0.1%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
BCPC vs MD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.7M | $493.8M |
| Net Profit | $40.3M | $33.7M |
| Gross Margin | — | — |
| Operating Margin | 20.5% | 9.9% |
| Net Margin | 14.9% | 6.8% |
| Revenue YoY | 8.1% | -1.7% |
| Net Profit YoY | 8.7% | 10.5% |
| EPS (diluted) | $1.25 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $270.7M | — | ||
| Q4 25 | $263.6M | $493.8M | ||
| Q3 25 | $267.6M | $492.9M | ||
| Q2 25 | $255.5M | $468.8M | ||
| Q1 25 | $250.5M | $458.4M | ||
| Q4 24 | $240.0M | $502.4M | ||
| Q3 24 | $239.9M | $511.2M | ||
| Q2 24 | $234.1M | $504.3M |
| Q1 26 | $40.3M | — | ||
| Q4 25 | $39.2M | $33.7M | ||
| Q3 25 | $40.3M | $71.7M | ||
| Q2 25 | $38.3M | $39.3M | ||
| Q1 25 | $37.1M | $20.7M | ||
| Q4 24 | $33.6M | $30.5M | ||
| Q3 24 | $33.8M | $19.4M | ||
| Q2 24 | $32.1M | $-153.0M |
| Q1 26 | — | — | ||
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 36.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | — | ||
| Q2 24 | 35.5% | — |
| Q1 26 | 20.5% | — | ||
| Q4 25 | 19.8% | 9.9% | ||
| Q3 25 | 20.4% | 13.8% | ||
| Q2 25 | 20.1% | 12.8% | ||
| Q1 25 | 20.4% | 7.0% | ||
| Q4 24 | 19.8% | 7.8% | ||
| Q3 24 | 20.0% | 6.6% | ||
| Q2 24 | 19.6% | -31.3% |
| Q1 26 | 14.9% | — | ||
| Q4 25 | 14.9% | 6.8% | ||
| Q3 25 | 15.1% | 14.5% | ||
| Q2 25 | 15.0% | 8.4% | ||
| Q1 25 | 14.8% | 4.5% | ||
| Q4 24 | 14.0% | 6.1% | ||
| Q3 24 | 14.1% | 3.8% | ||
| Q2 24 | 13.7% | -30.3% |
| Q1 26 | $1.25 | — | ||
| Q4 25 | $1.21 | $0.40 | ||
| Q3 25 | $1.24 | $0.84 | ||
| Q2 25 | $1.17 | $0.46 | ||
| Q1 25 | $1.13 | $0.24 | ||
| Q4 24 | $1.03 | $0.37 | ||
| Q3 24 | $1.03 | $0.23 | ||
| Q2 24 | $0.98 | $-1.84 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $72.9M | $375.2M |
| Total DebtLower is stronger | — | $570.5M |
| Stockholders' EquityBook value | $1.3B | $865.9M |
| Total Assets | $1.7B | $2.2B |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $72.9M | — | ||
| Q4 25 | $74.6M | $375.2M | ||
| Q3 25 | $65.1M | $340.1M | ||
| Q2 25 | $65.4M | $224.7M | ||
| Q1 25 | $49.9M | $99.0M | ||
| Q4 24 | $49.5M | $229.9M | ||
| Q3 24 | $73.7M | $103.8M | ||
| Q2 24 | $63.7M | $19.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $570.5M | ||
| Q3 25 | — | $577.2M | ||
| Q2 25 | — | $583.9M | ||
| Q1 25 | — | $590.5M | ||
| Q4 24 | — | $597.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $865.9M | ||
| Q3 25 | $1.3B | $890.7M | ||
| Q2 25 | $1.3B | $833.8M | ||
| Q1 25 | $1.2B | $789.2M | ||
| Q4 24 | $1.1B | $764.9M | ||
| Q3 24 | $1.2B | $732.5M | ||
| Q2 24 | $1.1B | $706.5M |
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | $2.2B | ||
| Q3 25 | $1.7B | $2.2B | ||
| Q2 25 | $1.7B | $2.1B | ||
| Q1 25 | $1.6B | $2.0B | ||
| Q4 24 | $1.6B | $2.2B | ||
| Q3 24 | $1.6B | $2.1B | ||
| Q2 24 | $1.6B | $2.0B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.70× | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $40.1M | $114.1M |
| Free Cash FlowOCF − Capex | $33.8M | — |
| FCF MarginFCF / Revenue | 12.5% | — |
| Capex IntensityCapex / Revenue | 2.3% | — |
| Cash ConversionOCF / Net Profit | 0.99× | 3.39× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $40.1M | — | ||
| Q4 25 | $67.3M | $114.1M | ||
| Q3 25 | $65.6M | $137.3M | ||
| Q2 25 | $47.3M | $137.2M | ||
| Q1 25 | $36.5M | $-117.5M | ||
| Q4 24 | $52.3M | $133.0M | ||
| Q3 24 | $51.3M | $91.8M | ||
| Q2 24 | $45.0M | $107.0M |
| Q1 26 | $33.8M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 12.5% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 2.3% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 0.99× | — | ||
| Q4 25 | 1.72× | 3.39× | ||
| Q3 25 | 1.63× | 1.91× | ||
| Q2 25 | 1.23× | 3.49× | ||
| Q1 25 | 0.98× | -5.66× | ||
| Q4 24 | 1.56× | 4.36× | ||
| Q3 24 | 1.52× | 4.72× | ||
| Q2 24 | 1.40× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
Segment breakdown not available.
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
